Efficacy and safety of once-weekly intravenous epoetin alfa in maintaining hemoglobin levels in hemodialysis patients

Francesco Locatelli, Giuseppe Villa, Piergiorgio Messa, Armando Filippini, Giuseppe Cannella, Giacomo De Ferrari, Agostino Naso, Egidio Rossi, Marco Formica, Luigi Lombardi, Ugo Rotolo, Ferruccio Conte

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background: Although an erythropoiesis-stimulating agent (ESA) is most frequently administered intravenously for treatment of anemia in patients with chronic kidney disease who are on dialysis, few studies have compared the efficacy of different intravenous (i.v.) dosing schedules. Methods: This multicenter, phase IIIb, open-label, controlled study randomized 289 stable hemodialysis patients to continue with conventional dosing of i.v. epoetin alfa or darbepoetin, or to switch to once-weekly i.v. epoetin alfa at the same cumulative weekly starting dose, to maintain hemoglobin levels at 11.0-13.0 g/dL, and within 1.0 g/ dL of the baseline value. Hemoglobin levels and ESA doses were recorded every 4 weeks for 28 weeks. Results: Hemoglobin levels fell significantly and ESA doses increased significantly between baseline and week 28 (mean of week 16-28 values) in the once-weekly epoetin alfa group, compared with the conventional treatment group (p

Original languageEnglish
Pages (from-to)412-420
Number of pages9
JournalJournal of Nephrology
Volume21
Issue number3
Publication statusPublished - 2008

Fingerprint

Epoetin Alfa
Hematinics
Renal Dialysis
Hemoglobins
Safety
Chronic Renal Insufficiency
Anemia
Dialysis
Appointments and Schedules
Therapeutics

Keywords

  • Anemia
  • Chronic kidney disease
  • Dialysis
  • Epoetin alfa
  • Erythropoiesis-stimulating agent
  • Frequency of administration

ASJC Scopus subject areas

  • Nephrology

Cite this

Locatelli, F., Villa, G., Messa, P., Filippini, A., Cannella, G., De Ferrari, G., ... Conte, F. (2008). Efficacy and safety of once-weekly intravenous epoetin alfa in maintaining hemoglobin levels in hemodialysis patients. Journal of Nephrology, 21(3), 412-420.

Efficacy and safety of once-weekly intravenous epoetin alfa in maintaining hemoglobin levels in hemodialysis patients. / Locatelli, Francesco; Villa, Giuseppe; Messa, Piergiorgio; Filippini, Armando; Cannella, Giuseppe; De Ferrari, Giacomo; Naso, Agostino; Rossi, Egidio; Formica, Marco; Lombardi, Luigi; Rotolo, Ugo; Conte, Ferruccio.

In: Journal of Nephrology, Vol. 21, No. 3, 2008, p. 412-420.

Research output: Contribution to journalArticle

Locatelli, F, Villa, G, Messa, P, Filippini, A, Cannella, G, De Ferrari, G, Naso, A, Rossi, E, Formica, M, Lombardi, L, Rotolo, U & Conte, F 2008, 'Efficacy and safety of once-weekly intravenous epoetin alfa in maintaining hemoglobin levels in hemodialysis patients', Journal of Nephrology, vol. 21, no. 3, pp. 412-420.
Locatelli, Francesco ; Villa, Giuseppe ; Messa, Piergiorgio ; Filippini, Armando ; Cannella, Giuseppe ; De Ferrari, Giacomo ; Naso, Agostino ; Rossi, Egidio ; Formica, Marco ; Lombardi, Luigi ; Rotolo, Ugo ; Conte, Ferruccio. / Efficacy and safety of once-weekly intravenous epoetin alfa in maintaining hemoglobin levels in hemodialysis patients. In: Journal of Nephrology. 2008 ; Vol. 21, No. 3. pp. 412-420.
@article{116039274b9d40b38aa0e90d6cdbafaa,
title = "Efficacy and safety of once-weekly intravenous epoetin alfa in maintaining hemoglobin levels in hemodialysis patients",
abstract = "Background: Although an erythropoiesis-stimulating agent (ESA) is most frequently administered intravenously for treatment of anemia in patients with chronic kidney disease who are on dialysis, few studies have compared the efficacy of different intravenous (i.v.) dosing schedules. Methods: This multicenter, phase IIIb, open-label, controlled study randomized 289 stable hemodialysis patients to continue with conventional dosing of i.v. epoetin alfa or darbepoetin, or to switch to once-weekly i.v. epoetin alfa at the same cumulative weekly starting dose, to maintain hemoglobin levels at 11.0-13.0 g/dL, and within 1.0 g/ dL of the baseline value. Hemoglobin levels and ESA doses were recorded every 4 weeks for 28 weeks. Results: Hemoglobin levels fell significantly and ESA doses increased significantly between baseline and week 28 (mean of week 16-28 values) in the once-weekly epoetin alfa group, compared with the conventional treatment group (p",
keywords = "Anemia, Chronic kidney disease, Dialysis, Epoetin alfa, Erythropoiesis-stimulating agent, Frequency of administration",
author = "Francesco Locatelli and Giuseppe Villa and Piergiorgio Messa and Armando Filippini and Giuseppe Cannella and {De Ferrari}, Giacomo and Agostino Naso and Egidio Rossi and Marco Formica and Luigi Lombardi and Ugo Rotolo and Ferruccio Conte",
year = "2008",
language = "English",
volume = "21",
pages = "412--420",
journal = "Journal of Nephrology",
issn = "1121-8428",
publisher = "Springer International Publishing",
number = "3",

}

TY - JOUR

T1 - Efficacy and safety of once-weekly intravenous epoetin alfa in maintaining hemoglobin levels in hemodialysis patients

AU - Locatelli, Francesco

AU - Villa, Giuseppe

AU - Messa, Piergiorgio

AU - Filippini, Armando

AU - Cannella, Giuseppe

AU - De Ferrari, Giacomo

AU - Naso, Agostino

AU - Rossi, Egidio

AU - Formica, Marco

AU - Lombardi, Luigi

AU - Rotolo, Ugo

AU - Conte, Ferruccio

PY - 2008

Y1 - 2008

N2 - Background: Although an erythropoiesis-stimulating agent (ESA) is most frequently administered intravenously for treatment of anemia in patients with chronic kidney disease who are on dialysis, few studies have compared the efficacy of different intravenous (i.v.) dosing schedules. Methods: This multicenter, phase IIIb, open-label, controlled study randomized 289 stable hemodialysis patients to continue with conventional dosing of i.v. epoetin alfa or darbepoetin, or to switch to once-weekly i.v. epoetin alfa at the same cumulative weekly starting dose, to maintain hemoglobin levels at 11.0-13.0 g/dL, and within 1.0 g/ dL of the baseline value. Hemoglobin levels and ESA doses were recorded every 4 weeks for 28 weeks. Results: Hemoglobin levels fell significantly and ESA doses increased significantly between baseline and week 28 (mean of week 16-28 values) in the once-weekly epoetin alfa group, compared with the conventional treatment group (p

AB - Background: Although an erythropoiesis-stimulating agent (ESA) is most frequently administered intravenously for treatment of anemia in patients with chronic kidney disease who are on dialysis, few studies have compared the efficacy of different intravenous (i.v.) dosing schedules. Methods: This multicenter, phase IIIb, open-label, controlled study randomized 289 stable hemodialysis patients to continue with conventional dosing of i.v. epoetin alfa or darbepoetin, or to switch to once-weekly i.v. epoetin alfa at the same cumulative weekly starting dose, to maintain hemoglobin levels at 11.0-13.0 g/dL, and within 1.0 g/ dL of the baseline value. Hemoglobin levels and ESA doses were recorded every 4 weeks for 28 weeks. Results: Hemoglobin levels fell significantly and ESA doses increased significantly between baseline and week 28 (mean of week 16-28 values) in the once-weekly epoetin alfa group, compared with the conventional treatment group (p

KW - Anemia

KW - Chronic kidney disease

KW - Dialysis

KW - Epoetin alfa

KW - Erythropoiesis-stimulating agent

KW - Frequency of administration

UR - http://www.scopus.com/inward/record.url?scp=52049113274&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=52049113274&partnerID=8YFLogxK

M3 - Article

C2 - 18587731

AN - SCOPUS:52049113274

VL - 21

SP - 412

EP - 420

JO - Journal of Nephrology

JF - Journal of Nephrology

SN - 1121-8428

IS - 3

ER -